Brief Title
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer
Official Title
A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA
Brief Summary
This pilot phase I/II trial studies the side effects and best of dose ipilimumab when given
together with local radiation therapy and to see how well it works in treating patients with
recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies,
such as ipilimumab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer
cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective
treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer
Detailed Description
PRIMARY OBJECTIVES:
1. To assess the safety of combining intratumoral anti-cytotoxic T-lymphocyte-associated
protein 4 (CTLA4) immunotherapy with local radiation therapy in patients with melanoma,
non-Hodgkin lymphoma, and colorectal carcinoma with a monotherapy ipilimumab safety lead-in.
SECONDARY OBJECTIVES:
1. To assess the induction of an anti-tumor immune responses using laboratory correlative
studies.
2. To determine tumor response rates and duration of response at unirradiated tumor sites
in patients with advanced malignancies.
3. To identify putative immunologic biomarkers of tumor response.
OUTLINE: This is a phase I dose-escalation study of ipilimumab, followed by a phase 2 study.
Only a few subjects participated in the phase 1 portion of this study. The phase 2 portion of
this study was not conducted.
Patients receive ipilimumab intratumorally on day 1 and undergo local radiation therapy
within 48 hours for at least 3 fractions.
After completion of study treatment, patients are followed up at 4 and 8 weeks, and then
every 24 weeks for 5 years.
Study Phase
Phase 1/Phase 2
Study Type
Interventional
Primary Outcome
Dose-limiting Toxicity
Secondary Outcome
Immune Response (Phase 2 Only)
Condition
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Intervention
Ipilimumab
Study Arms / Comparison Groups
Ipilimumab 25 mg
Description: Participants receive ipilimumab intratumorally on Day 1
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
3
Start Date
February 2013
Completion Date
June 2015
Primary Completion Date
November 2014
Eligibility Criteria
Inclusion Criteria:
- Willing and able to give written informed consent
- Before any study procedures are performed, subjects (or their legally acceptable
representatives) will have the details of the study described to them, and they
will be given a written informed consent document to read; then, if subjects
consent to participate in the study, they will indicate that consent by signing
and dating the informed consent document in the presence of study personnel
- Histologically confirmed malignancy
- In Phase 1, histologically confirmed melanoma.
- In Phase 2, histologically confirmed melanoma, non-Hodgkin lymphoma, or
colorectal carcinoma
- Must have failed at least one systemic therapy or be intolerant to at least one prior
systemic treatment
- Must have at least two lesions of evaluable size by modified World Health Organization
(mWHO)/Cheson criteria; one of two lesions must be amenable to biopsy (core or fine
needle aspirate) and intratumoral injection of up to 5ml (diameter >= 10mm)
- Subjects with asymptomatic brain metastases are eligible; (systemic steroids should be
avoided if possible, or the subject should be stable on the lowest clinically
effective dose, as steroids as they may interfere with the activity of ipilimumab if
administered at the time of the first ipilimumab dose)
- Must be at least 28 days since treatment with standard or investigational
chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, or immunotherapy,
and recovered from any clinically significant toxicity experienced during treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Life expectancy of >= 16 weeks
- Subjects must have baseline (screening/baseline) radiographic images, (e.g. brain,
chest, abdomen, pelvis, and bone scans with specific imaging tests to be determined by
the attending physician) within 6 weeks of initiation of ipilimumab
- White blood cell (WBC) >= 2000/uL (~2 x 10^9/L)
- Absolute neutrophil count (ANC) >= 1000/uL (~0.5 x 10^9/L)
- Platelets >= 75 x 10^3/uL (~75 x 10^9/L)
- Hemoglobin >= 9 g/dL (may be transfused)
- Creatinine =< 2.0 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for
subjects without liver metastasis =< 5 times for liver metastases
- Bilirubin =< 2.0 x ULN (except for subjects with Gilbert's syndrome, who must have a
total bilirubin of less than 3.0 mg/dL)
- No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B,
or hepatitis C
- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 26 weeks after the
last dose of investigational product, in such a manner that the risk of pregnancy is
minimized; WOCBP include any female who has experienced menarche and who has not
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation,
or bilateral oophorectomy) or is not post-menopausal; post-menopause is defined as:
- Amenorrhea >= 12 consecutive months without another cause, or
- For women with irregular menstrual periods and taking hormone replacement therapy
(HRT), a documented serum follicle stimulating hormone (FSH) level >= 35 mIU/mL
- Women who are using oral contraceptives, other hormonal contraceptives (vaginal
products, skin patches, or implanted or injectable products), or mechanical products
such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to
prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg,
vasectomy) should be considered to be of childbearing potential; WOCBP must have a
negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent
units of human chorionic gonadotropin [HCG]) within 72 hours before the start of
ipilimumab
- Men of fathering potential must be using an adequate method of contraception to avoid
conception throughout the study (and for up to 26 weeks after the last dose of
investigational product) in such a manner that the risk of pregnancy is minimized
Exclusion Criteria:
- Any other malignancy from which the patient has been disease-free for less than 5
years, with the exception of adequately treated and cured basal or squamous cell skin
cancer, superficial bladder cancer or carcinoma in situ of the cervix
- Autoimmune disease: patients with a history of inflammatory bowel disease, including
ulcerative colitis and Crohn's disease, are excluded from this study, as are patients
with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive
sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg,
Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g.
Guillain-Barre Syndrome and Myasthenia Gravis)
- Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of ipilimumab hazardous or obscure the
interpretation of adverse events (AEs), such as a condition associated with frequent
diarrhea
- Patients with underlying heart conditions who are deemed ineligible for surgery by
cardiology consult
- Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to
1 month before or after any dose of ipilimumab)
- A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4
inhibitor or agonist
- Concomitant therapy with any of the following: interleukin-2 (IL 2), interferon, or
other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive
agents; other investigation therapies; or chronic use of systemic corticosteroids
- A history of AEs with prior IL-2 or Interferon will not preclude subjects from
entering the current study
- Any investigational agents
- Immunosuppressive agents (unless required for treating potential AEs)
- Chronic systemic corticosteroids (unless required for treating treatment emergent AEs
or required for management of signs or symptoms due to brain metastases, upon
discussion with Bristol-Myers Squibb [BMS] medical monitor)
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (eg, infectious) illness
- Women of childbearing potential (WOCBP) who:
- Are unwilling or unable to use an acceptable method of contraception to avoid
pregnancy for their entire study period and for at least 8 weeks after cessation
of study drug, or
- Have a positive pregnancy test at baseline, or
- Are pregnant or breastfeeding
- Persons of reproductive potential must agree to use an adequate method of
contraception throughout treatment and for at least 8 weeks after ipilimumab is
stopped; sexually active WOCBP must use an effective method of birth control during
the course of the study, in a manner such that risk of failure is minimized; before
study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during
study participation and the potential risk factors for an unintentional pregnancy; all
WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the
pregnancy test is positive, the patient must not receive ipilimumab and must not be
enrolled in the study
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
George A. Fisher, MD, PhD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01769222
Organization ID
IRB-25597
Secondary IDs
NCI-2012-02988
Responsible Party
Principal Investigator
Study Sponsor
Stanford University
Collaborators
National Cancer Institute (NCI)
Study Sponsor
George A. Fisher, MD, PhD, Principal Investigator, Stanford University
Verification Date
January 2017